Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2009

View Archived Issues

GE-067 discriminates AD subjects from healthy subjects in phase II trial

CD-200-Fc fusion protein ameliorates Abeta-induced inflammation in vitro and in vivo

GlaxoSmithKline presents 5-HT2B receptor ligands for the treatment of fibrosis

M72/AS01E tuberculosis vaccine is safe and immunogenic in HIV-positive adults

Phase II data suggests safety and efficacy of lenalidomide monotherapy in multiple myeloma

Bayer Schering Pharma claims Toll-like receptors for treatment of inflammation

Roche describes MEK kinase inhibitors as oncolytics

AstraZeneca claims DGAT-1 inhibitors for the treatment of diabetes

Medicago reports additional results from H1N1 pandemic vaccine animal studies

Roche presents phase III Lucentis results in patients with retinal vein occlusion

FDA approves AstraZeneca and Bristol-Myers' Onglyza for type 2 diabetes

FDA issues complete response letter denying approval of Savient's BLA for Krystexxa

FDA advisory committee to review Auxilium's BLA for Xiaflex in Dupuytren's contracture

FDA issues complete response letter denying approval of ALS' NDA for Restanza in CAP

Lu-AA-21004 reduces anxiety and depression symptoms in MDD patients

Gabapentin is efficacious in treatment of cannabis dependence and withdrawal

FDA approves colchicine for acute gout and Mediterranean fever

FDA approves Genentech's Avastin for metastatic renal cell carcinoma

FDA lifts partial clinical hold of Icagen's ICA-105665 trial

Merck Serono requests re-examination of CHMP opinion for Erbitux in NSCLC

The FDA approves Lipsovir for the early treatment of cold sores

Purdue and Transcept sign exclusive U.S. license and collaboration agreement for Intermezzo

Shire reports results from phase III trial of velaglucerase alfa in type 1 Gaucher disease

Pharmasset reports preliminary results from phase I clinical trial of PSI-7851 in HCV

Cornerstone closes strategic transaction with Chiesi for Curosurf and issuance of shares

Organon and Ligand mutually terminate December 2008 collaboration and license agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...